Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that the inhalation of sodium pyruvate will reduce lung damage in patients
with Cystic Fibrosis (CF) by its ability to reduce levels of toxic reactive oxygen and
nitrogen compounds associated with the chronic inflammatory component of the disease. The
primary objective of the study is to assess the safety of inhaled sodium pyruvate in 0.9%
sodium chloride (saline) solution in people with CF. Further, to determine whether inhaled
sodium pyruvate will improve lung function, as determined by spirometry, or reduced
inflammatory markers in induced sputum of people with CF.